Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results
Haemonetics Corporation released its financial results for the second quarter of fiscal year 2027, covering the period ended September 26, 2026.
Stocks · News reference
Haemonetics Q2 2027 Earnings Call Transcript
Haemonetics (NYSE:HAE) reported second-quarter financial results on Thursday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — HAEMONETICS CORP (HAE)
Filed: 2026-11-05 AccNo: 0000313143-26-000150 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
Haemonetics (HAE) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates over the past three months. The company, which provides blood management systems, is positioned in the top 20% of Zacks-covered stocks based on estimate revisions, suggesting potential near-term stock price appreciation.
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $118 to $140.
Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.